304 related articles for article (PubMed ID: 34680588)
1. Comparative Cancer Cell Signaling in Muscle-Invasive Urothelial Carcinoma of the Bladder in Dogs and Humans.
Tsamouri MM; Steele TM; Mudryj M; Kent MS; Ghosh PM
Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680588
[TBL] [Abstract][Full Text] [Related]
2. Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans.
Knapp DW; Dhawan D; Ramos-Vara JA; Ratliff TL; Cresswell GM; Utturkar S; Sommer BC; Fulkerson CM; Hahn NM
Front Oncol; 2019; 9():1493. PubMed ID: 32039002
[TBL] [Abstract][Full Text] [Related]
3. Urinary bladder cancer in dogs, a naturally occurring model for cancer biology and drug development.
Knapp DW; Ramos-Vara JA; Moore GE; Dhawan D; Bonney PL; Young KE
ILAR J; 2014; 55(1):100-18. PubMed ID: 24936033
[TBL] [Abstract][Full Text] [Related]
4. Identification of a naturally-occurring canine model for early detection and intervention research in high grade urothelial carcinoma.
Dhawan D; Ramos-Vara JA; Utturkar SM; Ruple A; Tersey SA; Nelson JB; Cooper BR; Heng HG; Ostrander EA; Parker HG; Hahn NM; Adams LG; Fulkerson CM; Childress MO; Bonney PL; Royce C; Fourez LM; Enstrom AW; Ambrosius LA; Knapp DW
Front Oncol; 2022; 12():1011969. PubMed ID: 36439482
[TBL] [Abstract][Full Text] [Related]
5. Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies.
Sommer BC; Dhawan D; Ratliff TL; Knapp DW
Bladder Cancer; 2018 Apr; 4(2):149-159. PubMed ID: 29732386
[TBL] [Abstract][Full Text] [Related]
6. Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer.
Dhawan D; Hahn NM; Ramos-Vara JA; Knapp DW
PLoS Genet; 2018 Aug; 14(8):e1007571. PubMed ID: 30089113
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive gene expression analysis of canine invasive urothelial bladder carcinoma by RNA-Seq.
Maeda S; Tomiyasu H; Tsuboi M; Inoue A; Ishihara G; Uchikai T; Chambers JK; Uchida K; Yonezawa T; Matsuki N
BMC Cancer; 2018 Apr; 18(1):472. PubMed ID: 29699519
[TBL] [Abstract][Full Text] [Related]
8. Naturally Occurring Canine Invasive Urinary Bladder Cancer: A Complementary Animal Model to Improve the Success Rate in Human Clinical Trials of New Cancer Drugs.
Fulkerson CM; Dhawan D; Ratliff TL; Hahn NM; Knapp DW
Int J Genomics; 2017; 2017():6589529. PubMed ID: 28487862
[TBL] [Abstract][Full Text] [Related]
9. Naturally-occurring canine transitional cell carcinoma of the urinary bladder A relevant model of human invasive bladder cancer.
Knapp DW; Glickman NW; Denicola DB; Bonney PL; Lin TL; Glickman LT
Urol Oncol; 2000; 5(2):47-59. PubMed ID: 21227289
[TBL] [Abstract][Full Text] [Related]
10. DNMT1: an emerging target in the treatment of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Hahn NM; Waddell J; Olbricht GR; Zheng R; Stewart JC; Knapp DW
Urol Oncol; 2013 Nov; 31(8):1761-9. PubMed ID: 22609058
[TBL] [Abstract][Full Text] [Related]
11. Canine invasive transitional cell carcinoma cell lines: in vitro tools to complement a relevant animal model of invasive urinary bladder cancer.
Dhawan D; Ramos-Vara JA; Stewart JC; Zheng R; Knapp DW
Urol Oncol; 2009; 27(3):284-92. PubMed ID: 18562222
[TBL] [Abstract][Full Text] [Related]
12. Clinical, Pathological, and Ethical Considerations for the Conduct of Clinical Trials in Dogs with Naturally Occurring Cancer: A Comparative Approach to Accelerate Translational Drug Development.
Regan D; Garcia K; Thamm D
ILAR J; 2018 Dec; 59(1):99-110. PubMed ID: 30668709
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the molecular and immune landscape of canine bladder cancer.
Cronise KE; Das S; Hernandez BG; Regan DP; Dailey DD; McGeachan RI; Lana SE; Page RL; Gustafson DL; Duval DL
Vet Comp Oncol; 2022 Mar; 20(1):69-81. PubMed ID: 34021685
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring,
Rossman P; Zabka TS; Ruple A; Tuerck D; Ramos-Vara JA; Liu L; Mohallem R; Merchant M; Franco J; Fulkerson CM; Bhide KP; Breen M; Aryal UK; Murray E; Dybdal N; Utturkar SM; Fourez LM; Enstrom AW; Dhawan D; Knapp DW
Mol Cancer Ther; 2021 Nov; 20(11):2177-2188. PubMed ID: 34433660
[TBL] [Abstract][Full Text] [Related]
15. Population characteristics, management, and survival outcomes in muscle-invasive urothelial carcinoma undergoing radical resection: the MINOTAUR study.
Roupret M; Brouquet A; Colrat F; Diez-Andreu P; Prudent A; Chartier M; Gaudin AF; Bugnard F; Chillotti L; Bénard S; Branchoux S; Bellera C; Negrier S
World J Urol; 2023 Apr; 41(4):1069-1075. PubMed ID: 36929410
[TBL] [Abstract][Full Text] [Related]
16. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
Gandour-Edwards R; Lara PN; Folkins AK; LaSalle JM; Beckett L; Li Y; Meyers FJ; DeVere-White R
Cancer; 2002 Sep; 95(5):1009-15. PubMed ID: 12209684
[TBL] [Abstract][Full Text] [Related]
17. Urothelial Carcinoma Stem Cells: Current Concepts, Controversies, and Methods.
Hatina J; Parmar HS; Kripnerova M; Hepburn A; Heer R
Methods Mol Biol; 2018; 1655():121-136. PubMed ID: 28889382
[TBL] [Abstract][Full Text] [Related]
18. Targeting canine bladder transitional cell carcinoma with a human bladder cancer-specific ligand.
Lin TY; Zhang H; Wang S; Xie L; Li B; Rodriguez CO; de Vere White R; Pan CX
Mol Cancer; 2011 Jan; 10(1):9. PubMed ID: 21272294
[TBL] [Abstract][Full Text] [Related]
19. NMR-based metabolomics study of canine bladder cancer.
Zhang J; Wei S; Liu L; Nagana Gowda GA; Bonney P; Stewart J; Knapp DW; Raftery D
Biochim Biophys Acta; 2012 Nov; 1822(11):1807-14. PubMed ID: 22967815
[TBL] [Abstract][Full Text] [Related]
20. Commentary on "Prognostic effect of carcinoma in situ in muscle-invasive urothelial carcinoma patients receiving neoadjuvant chemotherapy.".
Thomas DE; Kaimakliotis HZ; Rice KR; Pereira JA; Johnston P; Moore ML; Reed A; Cregar DM; Franklin C; Loman RL; Koch MO; Bihrle R; Foster RS; Masterson TA; Gardner TA; Sundaram CP; Powell CR; Beck S; Grignon DJ; Cheng L; Albany C; Hahn NM
Urol Oncol; 2018 Jul; 36(7):345. PubMed ID: 29880459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
